98%
921
2 minutes
20
is a member of the non-tuberculous mycobacteria (NTM) group, responsible for chronic infections in individuals with cystic fibrosis (CF) or those otherwise immunocompromised. While viewed traditionally as an opportunistic pathogen, increasing research into in recent years has highlighted its continued evolution into a true pathogen. This is demonstrated through an extensive collection of virulence factors (VFs) possessed by this organism which facilitate survival within the host, particularly in the harsh environment of the CF lung. These include VFs resembling those of other Mycobacteria, and non-mycobacterial VFs, both of which make a notable contribution in shaping interaction with the host. continued acquisition of VFs is cause for concern and highlights the need for novel vaccination strategies to combat this pathogen. An effective vaccine must be suitably designed for target populations (i.e., individuals with CF) and incorporate current knowledge on immune correlates of protection against infection. Vaccination strategies must also build upon lessons learned from ongoing efforts to develop novel vaccines for other pathogens, particularly (); decades of research into has provided insight into unconventional and innovative vaccine approaches that may be applied to . Continued research into pathogenesis will be critical for the future development of safe and effective vaccines and therapeutics to reduce global incidence of this emerging pathogen.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928063 | PMC |
http://dx.doi.org/10.3389/fmicb.2022.842017 | DOI Listing |
Cardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Secondary mitral regurgitation (SMR) remains a prevalent and challenging complication in patients with heart failure (HF), associated with poor prognosis despite optimal guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy. Current American and European guidelines recommend GDMT as first-line therapy, with transcatheter edge-to-edge repair (TEER) reserved for severe symptomatic SMR patients who remain refractory. However, both guidelines preceded the reporting of pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, and EFFORT) and emerging evidence in new clinical scenarios.
View Article and Find Full Text PDFJ Pediatr Urol
August 2025
Department of Pediatric Surgery, Rigshospitalet, Clinical Medicine, Copenhagen University, Copenhagen, Denmark; Department of Women's and Children's Health, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address:
The European Reference Networks (ERNs) initiative was started by the European Commission. The initiative was launched in 2017 in response to the 2011 EU Directive on Cross-Border Healthcare (Directive 2011/24/EU), which emphasized the need to improve healthcare for patients with rare diseases and complex conditions across the European Union. Currently, 24 ERNs are available for rare diseases.
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
Protein Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab, Alexandria, 21934, Egypt. Electronic address:
The growing demand for sustainable agriculture imposes innovative biocontrol strategies to mitigate phytopathogen threats while reducing dependence on chemical pesticides. This review explores the current knowledge on enzyme-based biocontrol, focusing on hydrolytic enzymes (e.g.
View Article and Find Full Text PDFAnn Pharm Fr
September 2025
Nantes Université, CHU Nantes, Pharmacie, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Regenerative Medicine and Skeleton, RMeS, UMR 1229, F-44000 Nantes, France.
Objectives: Patients with a jejunostomy use their tube daily in most cases, which exposes them to various complications. However, to our knowledge, the current literature is limited regarding available educational interventions or tools for these patients, and no specific competency framework for surgical jejunostomy has been developed yet. This project aimed to develop a unique and adapted competency framework for surgical jejunostomy patients through a multiprofessional and consensus-driven approach and to create a fun educational tool based on this framework to promote an effective educational approach.
View Article and Find Full Text PDFDrug Metab Dispos
August 2025
Translational Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Princeton, New Jersey.
1β-Hydroxydeoxycholic acid (1β-OH DCA) in plasma has been shown to be a promising biomarker to assess drug-drug interaction (DDI) with a strong CYP3A inducer or a strong CYP3A inhibitor. The changes in total 1β-OH DCA (sum of 1β-OH DCA, 1β-OH glycine deoxycholic acid, and 1β-OH taurine deoxycholic acid equivalents) were more significant than those observed from 4β-hydroxycholesterol, which has been limited to the identification of CYP3A inducers, not CYP3A inhibitors. The significant reduction in total 1β-OH DCA in response to strong CYP3A inhibitors led us to further explore its utility as a biomarker for DDI with moderate CYP3A inhibitors.
View Article and Find Full Text PDF